Patents by Inventor Kevin R. Engh
Kevin R. Engh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040156898Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: February 2, 2004Publication date: August 12, 2004Inventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska
-
Publication number: 20040156897Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior arts. This formulation minimnizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: February 2, 2004Publication date: August 12, 2004Inventors: Yihong Qiu, J. Daniel Bollinger, Howard S. Cheskin, Sandeep Dutta, Kevin R. Engh, Richard P. Poska
-
Patent number: 6720004Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: GrantFiled: August 8, 2002Date of Patent: April 13, 2004Assignee: Abbott LaboratoriesInventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska
-
Patent number: 6713086Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: GrantFiled: August 8, 2002Date of Patent: March 30, 2004Assignee: Abbott LaboratoriesInventors: Yihong Qiu, J. Daniel Bollinger, Howard S. Cheskin, Sandeep Dutta, Kevin R. Engh, Richard P. Poska
-
Publication number: 20030118656Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: August 8, 2002Publication date: June 26, 2003Inventors: Yihong Qiu, J. Daniel Bollinger, Howard S. Cheskin, Sandeep Dutta, Kevin R. Engh, Richard P. Poska
-
Publication number: 20030104057Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: August 8, 2002Publication date: June 5, 2003Inventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska
-
Patent number: 6528090Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: GrantFiled: December 22, 2000Date of Patent: March 4, 2003Assignee: Abbott LaboratoriesInventors: Yihong Qiu, J. Daniel Bollinger, Howard S. Cheskin, Sandeep Dutta, Kevin R. Engh, Richard P. Poska
-
Patent number: 6511678Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: GrantFiled: December 22, 2000Date of Patent: January 28, 2003Assignee: Abbott LaboratoriesInventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska
-
Publication number: 20020132010Abstract: The present invention is directed to a new process for granulating valproate compounds, such as divalproex sodium, in which the compound is melted in the absence of a binder and admixed with one or more excipeints to produce granules. The resulting dosage forms have an increased drug loading factor in the range of 75 w/w % to 90 w/w %.Type: ApplicationFiled: December 22, 2000Publication date: September 19, 2002Inventors: Yihong Qui, Todd E. Chermak, Kevin R. Engh, Lynn Faitsch, Russell T. Slade
-
Publication number: 20020127277Abstract: The present invention is directed to an aqueous process for granulating valproate compounds, in which the pH of the granulation solution is maintained at a pH of 5 or below. The invention is also directed to dosage forms in which the residual content of organic solvents is reduced to a level of 0.2 w/w % or less.Type: ApplicationFiled: December 22, 2000Publication date: September 12, 2002Inventors: Yihong Qiu, Kevin R. Engh, Lynn Faitsch, Russell T. Slade
-
Patent number: 6383517Abstract: A process for preparing a solid formulation of a lipid-regulating agent comprising dissolving said lipid-regulating agent particles in a surfactant solution, premixing an excipient, wet granulating the mixture, drying the mixture and forming a finished dosage form.Type: GrantFiled: January 29, 1999Date of Patent: May 7, 2002Assignee: Abbott LaboratoriesInventors: Yihong Qiu, Venkatramana M. Rao, Kevin R. Engh, Thomas L. Reiland
-
Patent number: 6368622Abstract: A process for preparing a solid formulation of a lipid-regulating agent comprising forming a mixture of said lipid-regulating agent with a surfactant; granulating said mixture by melting, mixing, and congealing said mixture; and optionally forming a finished dosage form.Type: GrantFiled: January 29, 1999Date of Patent: April 9, 2002Assignee: Abbott LaboratoriesInventors: Yisheng Chen, Kevin R. Engh, Yihong Qiu, Thomas L. Reiland
-
Publication number: 20020031549Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: June 8, 2001Publication date: March 14, 2002Inventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska, Kenneth W. Sommerville
-
Publication number: 20020025341Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: June 8, 2001Publication date: February 28, 2002Inventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska, Kenneth W. Sommerville
-
Publication number: 20010020039Abstract: A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.Type: ApplicationFiled: December 22, 2000Publication date: September 6, 2001Inventors: Yihong Qiu, J. Daniel Bollinger, Sandeep Dutta, Howard S. Cheskin, Kevin R. Engh, Richard P. Poska
-
Publication number: 20010006655Abstract: A process for preparing a solid formulation of a lipid-regulating agent comprising forming a mixture of said lipid-regulating agent with a surfactant; granulating said mixture by melting, mixing, and congealing said mixture; and optionally forming a finished dosage form.Type: ApplicationFiled: January 29, 1999Publication date: July 5, 2001Inventors: YISHENG CHEN, KEVIN R. ENGH, YIHOUNG QIU, THOMAS L. REILAND
-
Patent number: 6180138Abstract: A process for the preparation of solid formulations of a lipid-regulating agent having enhanced dissolution and absorption characteristics, in which a micronized mixture of the said lipid-regulating agent, and optionally one or more excipients, is suspended in a surfactant solution, dried and optionally granulated, and optionally converted to a finished dosage form.Type: GrantFiled: January 29, 1999Date of Patent: January 30, 2001Assignee: Abbott LaboratoriesInventors: Kevin R. Engh, Yihong Qiu, Thomas L. Reiland
-
Patent number: 6150410Abstract: Pharmaceutical formulations of acidic pharmacologic agents which demonstrate improved uniformity of release over the wide range of pH values encountered between the stomach and intestinal tract comprise an acidic pharmacologic agent dissolved or dispersed in a matrix comprising about 10 weight percent to about 40 weight percent of a a neutral water-swellable hydrophilic polymer and 20 weight percent to about 50 weight percent of an acid-soluble polymer which swells in water at pH values above about 5. A particularly preferred formulation comprises divalproex sodium. Also disclosed are pre-tablet granulations and process for preparing both the pre-tablet granulation and the tablet unit dosage form.Type: GrantFiled: January 25, 2000Date of Patent: November 21, 2000Assignee: Abbott LaboratoriesInventors: Kevin R. Engh, Yihong Qiu, Venkatramana M. Rao